WEBINAR : Biotech IPOs: Trends for Financing Innovation
FEATURING: Egnyte & Credit Suisse
DURATION: 1 Hour
Today, there are ~300% more publicly-traded biotech companies than just 25 years ago. Why? Public market investors are more excited by the promise of new medicines curing diseases than ever before.
However, recently, major M&A activity, landmark clinical readouts, and geopolitics have created a highly-dynamic IPO landscape for biotech companies. In this session, co-hosted by Credit Suisse, we discuss the recent market trends and IPO landscape for emerging life sciences companies.
In this webinar, you will learn:
Biotech market performance in 2019
Recent events translating into growth in the industry
Biotech IPO outlook for 2020